Safety, Pharmacokinetics and Pharmacodynamics of Remogliflozin Etabonate, a Novel SGLT2 Inhibitor, and Metformin When Co-Administered in Subjects With Type 2 Diabetes Mellitus

BMC pharmacology & toxicology - United Kingdom
doi 10.1186/2050-6511-14-25
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search